Compare AISP & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | EQ |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | 63 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.7M | 64.5M |
| IPO Year | N/A | 2018 |
| Metric | AISP | EQ |
|---|---|---|
| Price | $2.53 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 423.4K | 396.7K |
| Earning Date | 05-14-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | $222.88 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $3.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $0.29 |
| 52 Week High | $7.20 | $2.70 |
| Indicator | AISP | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 52.78 |
| Support Level | $2.36 | $1.22 |
| Resistance Level | $2.85 | $2.13 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 93.27 | 69.30 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture. Airship AI's software allows customers to view structured data both in real-time as well as to conduct searches on the structured data at a later point in time.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.